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ABSTRACT
Nonmyeloablative transplantation (NMT) is intended to be less toxic than traditional allografts, but such
regimens as fludarabine/melphalan still pose a significant risk of graft-versus-host disease (GVHD). We used
Campath-1H in an attempt to reduce the risk of GVHD in NMT. Patients with hematologic malignancies
suitable for allogeneic transplantation underwent transplantation using a regimen of fludarabine 30 mg/m2 on
days 5 to 2 (total, 120 mg/m2), total body irradiation of 200 cGy on day 1, and Campath-1H 20 mg/day
on days 7 to 3 (total dose, 100 mg). After loss of graft in 5 of the first 6 patients, the protocol was amended
by decreasing the Campath-1H dose to 20 mg on days 4 and 3 and 10 mg on day 2 (total dose, 50 mg) for
all subsequent patients. GVHD prophylaxis consisted of only cyclosporine, due to the immunosuppressive
effect of Campath-1H. Patients received prophylactic acyclovir, fluconazole, and a quinolone. Other require-
ments included creatinine clearance > 25 mL/min, diffusing capacity > 45% of predicted, and cardiac ejection
fraction > 40%. Twenty-five patients with hematologic malignancies entered the study. The median age was
40 years (range, 26-71 years). Median time to engraftment (defined as a neutrophil count of 500 mm3 and a
platelet count of 20,000 mm3 without platelet support on at least 2 days) was 19 days (range, 9-32 days). All
patients who were treated after the amendment engrafted with 90%-100% donor cells by day 100 except for
2 early deaths. Acute GVHD developed in 40% of the patients. Patients who underwent related transplants
developed GVHD after donor lymphocyte infusions for poor engraftment or relapse whereas those undergoing
unrelated transplants developed GVHD de novo. Two patients (8%) developed chronic GVHD, and 48% had
cytomegalovirus reactivation, which was easily managed medically. Nonrelapse mortality within the first 12
months was 12%; 32% of the patients survived at a median of 269 days. We conclude that Campath-1H,
fludarabine, and melphalan is a reasonable preparative regimen for reduced-intensity transplantation with a
low nonrelapse mortality, but that issues of GVHD remain problematic, due to either the use of donor
lymphocyte infusions or the use of volunteer unrelated donors.
© 2006 American Society for Blood and Marrow Transplantation
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Bone marrow transplantation was originally devel-
ped to allow replacement of diseased marrow by new
tem cells after ablative chemotherapy with or without
adiation therapy. In the last decade, it has become t
68pparent that immunologic effects of transplanted
ells, graft-versus-host disease (GVHD), and graft-
ersus-tumor effect play a large role in the eradication
f malignancy in transplant recipients [1,2]. This has
een evident because patients undergoing allogeneic
ransplantation have a lower recurrence rate that those
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Reduced-Intensity Conditioning Campath 869ndergoing syngeneic transplantation; moreover, those
atients who develop GVHD experience a lower relapse
ate [3-5]. This effect has been most apparent in trans-
lantation for chronic myeloid leukemia (CML), al-
hough it has also been noted for acute myeloid leuke-
ia, multiple myeloma, and lymphoma. Furthermore,
he use of donor lymphocyte infusions has been shown
o achieve remission in patients who have relapsed
osttransplantation, especially those with molecular
elapse of CML [6,7].
Nonmyeloablative transplantation (NMT), which
ses a less intense preparative regimen but is signiﬁ-
antly immunosuppressive to allow donor engraft-
ent, has permitted older patients and those with
omorbid conditions to undergo transplantation for
ematologic malignancies. Engraftment and GVHD
ave remained a major problem in NMT, often lead-
ng to other complications, including infection and
ultiorgan failure. Thus, appropriate GVHD pro-
hylaxis is key in an attempt to balance the beneﬁts
nd risks of these transplantations.
Traditional approaches to prevent GVHD have
ncluded immunosuppressive combinations of cyclo-
porine and methotrexate, cyclosporine alone, and ta-
rolimus and mycophenolate mofetil. A novel ap-
roach is to use Campath-1H (alemtuzumab) for the
revention of GVHD. Campath-1H is a humanized
ntibody against the CD52 antigen that is highly ex-
ressed on human lymphocytes and monocytes. This
ntigen is also expressed on dendritic cells [8]. These
ells present recipient (host) antigens to donor cells,
esulting in the induction of GVHD by the donor cells.
ampath-1H is lympholytic and depletes the lympho-
ytes that cause GVHD. It also destroys the recipient
ntigen-presenting cells (dendritic cells), providing an
dditional mechanism for preventing GVHD. Cam-
ath-1H can be added to a cyclosporine and/or metho-
rexate regimen given posttransplantation.
The present protocol was designed to test the
easibility of a nonmyeloablative regimen with ade-
uate immunosuppression to allow engraftment and
revent GVHD but permit a graft-versus-tumor ef-
ect. We report a prospective study of nonmyeloabla-
ive allogeneic transplantation for hematologic malig-
ancies using Campath-1H as an in vivo agent of
rophylaxis of GVHD followed by ﬂudarabine and
hen by 200 cGy of total body irradiation (TBI).
ETHODS
atients and Donors
The Institutional Review Board of Weill Medical
ollege of Cornell University approved this study.
ritten informed consent was obtained from all pa-
ients. Patients with hematologic malignancies suit-
ble for therapy with allogeneic transplantation were iligible. Patients with acute leukemia required 10%
lasts in the marrow at the time of transplantation. An
LA-compatible donor, related or unrelated, allow-
ng only 1 antigen mismatch was required. Molecular
echniques were used for HLA-A, -B, -C, -DRB1, and
DQB1 loci (high-resolution) for HLA typing for pa-
ients and unrelated donors. For related donors, HLA
yping was done by serologic techniques for HLA-A,
B, and -C and by high-resolution molecular tech-
iques for HLA-DRB1 and -DQB1. Conﬁrmatory
esting was done for all patients and donors before the
nal donor selection. Donors were referred from the
ational Marrow Donor Program or other registries
nd were accepted for this protocol only if peripheral
lood progenitor cells would be available. Patients had
o be age 18 years or older; have a life expectancy of at
east 12 weeks; have an Eastern Cooperative Oncology
roup (ECOG) performance status of 0, 1, or 2; and
ad to be ineligible or unwilling to undergo a myelo-
blative standard allogeneic transplantation. Require-
ents also included a measured or calculated creati-
ine clearance of at least 25 mL/min, no active or
ncontrolled infection or medical condition, no evi-
ence of impaired hepatic function (deﬁned as a bili-
ubin level 1.5 times the upper limit of normal or an
lanine aminotransferase or aspartate aminotransfer-
se level  5 times normal), satisfactory pulmonary
unction (with a diffusing capacity of the lung for
arbon dioxide of at least 45% of predicted), and
easonable cardiac function (with an ejection fraction
f at least 40% of predicted).
reparative Regimen
The conditioning pretransplantation regimen con-
isted of ﬂudarabine 30 mg/m2 on days 5 to 2 (total,
20 mg/m2), TBI 200 cGy on day 1, and Cam-
ath-1H 20 mg/day on days7 to3 (total, 100 mg).
fter loss of graft occurred in 5 of the ﬁrst 6 patients
ho underwent this regimen, the protocol was
mended to decrease the Campath-1H dose to 20 mg
n days 3 and 4 and 10 mg on day 2 (total, 50
g) for all subsequent patients. Dosing of all drugs
as based on actual body weight. TBI (200 cGy) was
dministered using a linear accelerator without lung
hielding on day 1. Allogeneic donor hematopoietic
tem cells were infused on day 0 using standard donor
nfusion techniques. Completion of infusion of the
tem cells was deﬁned as day 0 for the purpose of
ngraftment and other posttransplantation events.
VHD Prophylaxis and Therapy
In addition to the Campath-1H, cyclosporine A
Sandimmune; Novartis Pharmaceuticals) was started
n day 1 at a dose of 3 mg/kg/day IV given in 2
ivided doses. Oral cyclosporine was given as soon as
t could be tolerated. Levels were monitored weekly to
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T. Shore et al.870nsure that they were within the therapeutic range.
he dose was reduced if a patient exhibited signs of
oxicity, including nephrotoxicity, uncontrollable hy-
ertension, or neurologic toxicity. Later, the dose was
educed by 10% per week beginning on day 100.
VHD was graded and staged according to published
riteria [9].
Patients who developed grade 2-4 GVHD were
reated with methylprednisolone (or its equivalent) 2
g/kg/day in divided doses initially and then reduced
ppropriately. For steroid-refractory GVHD, other
herapy was provided at the discretion of the treating
hysician.
upportive Care
Patients received supportive care according to in-
titutional guidelines for allogeneic transplant recipi-
nts. The peripheral blood progenitor cells were in-
used on the inpatient unit.
himerism
Chimerism studies were performed by means of
uorescence in situ hybridization for X and Y chro-
osomes or by gene ampliﬁcation of highly polymor-
hic repetitive loci called VNTRs (variable number of
andem repeats) or STRs (small tandem repeats) (The
lood Center of Southeastern Wisconsin). Toward
he end of the study, samples were sent for CD3
able 1. Patient/Donor Proﬁle
Diagnosis/Stage Prior SCT
1 Follicular small cleaved lymphoma stage 4 No
2 MDS No
3 Secondary AML/CR1 No
4 Secondary AML/CR1 No
5 AML/PR No
6 Secondary AML/CR1 No
7 CML/CR post blast crisis No
8 Secondary AML/CR1 No
9 Secondary AML/CR1 No
10 Secondary AML/CR1 No
11 Hodgkin’s/Rel 1 Yes
12 Hodgkin’s/rel 1 Yes
13 AML/rel 1 Yes
14 AML/MPD/MM No
15 CML/CP No
16 Secondary AML/CR1 No
17 HD/refractory relapse Yes
18 Mantle cell/rel 1 No
19 AML/CR2 No
20 AML/CR2 No
21 Mantle cell/rel 1 Yes
22 Mantle cell/CR 1 No
23 Follicular mixed cell lymphoma/rel 2 Yes
24 AML/CR/CR1 No
25 Diffuse large cell lymphoma/relapse Yes
DS, myelodysplastic syndrome; AML, acute myelogenous leukem
chronic myelogenous leukemia; MPD, myeloproliferative disorder; HDhimerism instead of just whole-blood chimerism,
ven though many of the patients had only whole-
lood chimerism studies. Complete donor chimerism
as deﬁned by lack of detection of the previously
etermined recipient DNA, whereas mixed chimerism
as quantiﬁed as the percentage of donor/recipient
NA by the foregoing method. All patients were
ssessed for chimerism in peripheral blood at days 30,
5, 60, and 90 using a standard chimerism assay. Bone
arrow evaluations were done at days 30 and 100.
onor Lymphocyte Infusions
Donor lymphocyte infusions were given to pa-
ients without GVHD if 50%-90% chimerism existed
n or after day 60. Lymphocyte infusions were also
iven to patients with residual malignancy as deter-
ined by marrow evaluation or with clinical evidence
f relapse. The infusion consisted of 1  107 CD3
ells/kg recipient’s weight. The dose was escalated as
ecessary at 4- to 8-week intervals.
tudy Endpoints/Statistical Analysis
This study was done to evaluate the ability of
ampath-1H to reduce GVHD post–nonmyelobla-
ive allogeneic transplantation in patients with hema-
ologic malignancies. Patients were assessed in terms
f engraftment kinetics and regimen-related toxicity.
Using the null hypothesis that the transplantation-
Patient Donor
ears) Sex CMV Sex CMV Type HLA
0 F () M () Related Match
4 M () F () Related Match
7 F () F () Related Match
7 M () M () Unrelated Mismatch
7 F () F () Unrelated Mismatch
1 M () M () Unrelated Match
6 M () M () Related Match
0 F () F () Related Match
1 M () M () Unrelated Match
3 M () F () Related Match
6 M () F () Related Match
4 F () M () Unrelated Match
8 F () F () Related Match
0 M () F () Unrelated Match
3 M () F () Unrelated Match
6 M () F () Related Match
2 M () M () Unrelated Mismatch
3 M () F () Related Match
5 F () M () Unrelated Match
8 M () M () Unrelated Mismatch
8 M () F () Related Match
6 F () F () Related Match
9 M () M () Related Match
9 M () M () Related Match
5 F () F () Related Mismatch
, complete remission; rel, relapse; MM, multiple myeloma; CML,Age (y
5
5
5
5
5
6
6
6
7
6
2
3
5
7
6
6
5
6
5
6
6
5
4
6
6
ia; CR
, Hodgkin’s disease.
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Reduced-Intensity Conditioning Campath 871elated mortality (TRM) rate, p, is .15, compared with
he alternative hypothesis that p is .30, TRMwas to be
ssessed at 3 stages, with 15 patients entered per stage.
e planned to enter a maximum of 45 patients.
The following decision rule was used:
Stage N Reject the null hypothesis that p < .15
1 15 If >5 of 15 patients experience TRM
2 30 If >8 of 30 patients experience TRM
3 45 If >14 of 45 patients experience TRM
Accrual was to continue as long as 1 of the stop-
ing criteria was not met. The signiﬁcance level and
ower of this design were .08 and .85, respectively.
ESULTS
atient Characteristics
Twenty-ﬁve patients underwent transplantation
ollowing our protocol from June 25, 2002 through
ctober 21, 2004. Patient and donor characteristics
re given in Table 1. The median patient age was 60
ears (range, 26-71 years). Six patients (24%) had
ndergone a previous autologous transplantation. Fif-
een patients (60%) received a related transplant, and
0 (40%) received an unrelated transplant. The me-
ian follow-up was 269 days (range, 47-1109 days).
ecovery/Engraftment
Most of the patients received grade 3-4 myelosup-
ression. Engraftment was deﬁned as a neutrophil
ount of 500/mm3 and a platelet count of 20,000/mm3
ithout platelet support for at least 2 days. Twelve
atients had a platelet nadir of  20,000/mm3 at a
edian of day 5 posttransplantation (range, 0-22
ays). These patients had a median platelet recovery,
s deﬁned earlier, by day 6 (range, 1-31 days). One
atient never recovered his platelet count and re-
ained transfusion-dependent. Thirteen patients had
platelet count that did not drop below 20,000/mm3.
Twenty-four patients had a nadir neutrophil count
f  500/mm3 on median day 7 (range, 4-23 days).
hese patients recovered their absolute neutrophil
ount to  500/mm3 by median day 20 (range, 10-37
ays).
The median day of engraftment post–stem cell
nfusion was 19 days (range, 9-37 days). One patient
id not engraft.
himerism
Chimerism studies were performed in all but 2
atients (Table 2). Lineage-speciﬁc chimerism studies
ere performed in 2 patients, and whole-blood chi-
erism was available in all patients. Of the ﬁrst 6
atients on study, 4 achieved donor chimerism of 
5% and 2 achieved donor chimerism of 50%-86%.
owever, 5 of the 6 patients exhibited a progressiveecline in the donor percentage of cells, and 3 of those
atients relapsed.
The protocol was then amended to decrease the
lemtuzumab dose to 50 mg. Of the 19 patients en-
olled on the amended version of the protocol, 16
84%) had full donor chimerism  90% by day 100.
wo patients did not have chimerism testing done
protocol violation), and 1 of these died before day
00. The third patient with  90% chimerism died
efore day 100 with only 75% donor cells. Two pa-
ients had a progressive loss of chimerism associated
ith relapse.
onor Lymphocyte Infusion
Eleven patients (44%) received donor lymphocyte
nfusion (DLI), 5 to treat active disease and 7 due to poor
onor chimerism (Table 3). One patient received DLI
or both reasons. Only 1 patient exhibited a beneﬁt from
LI in terms of achieving a clinical response.
VHD
Two of the ﬁrst 6 patients on study developed
VHD, 1 patient with grade 2 acute GVHD with
ubsequent chronic GVHD and 1 patient with grade 4
cute GVHD (Figure 1). Of the 19 patients on the
mended protocol, 10 (52.6%) developed acute GVHD.
able 2. Chimerism
Chimerism - % donor cells (day posttransplantation / 10 days)
Day 30 Day 45 Day 60 Day 90 Day 100
1 50 41 24
2 86 5
3 99 99 40
4 99 100 98
5 95 98 85 85 60
6 99 99 100 55
mended protocol
7 15 20 20 10 15
8 9 95 75 60 90
9 98 98 100 98 98
0 100 100 99 100
1 100 100
2 90 100 95 90
3 85 90 90 100 55
4 75
5 100 100 100
6 100 100 95
7
8 100 85
9 100 95 100 95
0 100
1 55 75 98
2 95 95 80 85
3
4 95 98 98 95
50 PB CD3
5 90 60 40 105 PB CD3 2 PB CD3
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T. Shore et al.872ne patient had grade 1, 3 patients had grade 2, 2
atients had grade 3, and 4 patients had grade 4 acute
VHD.
In the amended protocol, 11 patients had related
onors. Seven required DLI. Of those 7, 2 developed
evere grade 4 GVHD, 1 had grade 3 GVHD with
nfectious complications resulting in death, and 1 had
rade 2 GVHD. One patient developed extensive
hronic GVHD after DLI.
Seven patients received an unrelated transplant
fter the amendment. One had grade 1, 2 had grade 2,
nd 1 had grade 4 GVHD. Only 1 case of grade 2
VHD was related to DLI. Table 4 summarizes the
esults before and after amendment.
ytomegalovirus Reactivation
Cytomegalovirus (CMV) reactivation occurred in
3 of 25 patients (48%). This was easily treated with
able 3. Donor Lymphocyte Infusion
Patient no. Day of DLI Reason
1 170 Poor chimerism, Relapse Prog
3 219 Poor chimerism Rela
5 127 Relapse Prog
7 63 Relapse Rem
8 78 Poor chimerism Deat
12 222, 269 Poor chimerism Grad
16 205, 239 Relapse Deat
18 140 Poor chimerism Impr
inf
22 190 Poor chimerism Impr
24 101 Relapse Prog
25 86 Poor chimerism CD 3
10.000.00
Time (month
1.0
0.8
0.6
0.4
0.2
0.0
Probability
of aGVHDFigure 1. Cumulative incidence oanciclovir or, alternatively, foscarnet. No patient de-
eloped signiﬁcant CMV disease, and no patient died
ue to CMV. Only 2 patient–donor pairs were CMV
eronegative/seronegative, and neither of these pa-
ients developed CMV viremia.
urrent Status
Overall, 14 patients (56%) died due to relapse and
ssociated complications. Four patients (16%) died of
RM in the ﬁrst 6 months (Figure 2). Eight patients
emain alive, 2 in relapse, for an overall survival of
2% at a median of 269 days (Table 5).
The initial 6 patients received ﬂudarabine/TBI in
ddition to 100 mg of Campath-1H. Five of these 6
atients engrafted but lost their graft within 100 days;
his was associated with relapse of primary disease in 3
nd with progression of underlying malignancy in 2.
wo of these patients subsequently underwent second
Outcome
chronic GVHD due to DLI
to GVHD (grade 4)
HD, then relapse, response to salvage therapy
to relapse and GVHD (grade 4)
nt in chimerism but development of grade 3 GVHD, associated
complications, and death
nt in chimerism but progression of disease
rism only 3%; relapse
30.00
Censoredressed
psed
ressed
ission,
h due
e 2 GV
h due
oveme
ectious
oveme
ression20.00
s)
f acute grade 2-4 GVHD.
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Reduced-Intensity Conditioning Campath 873ransplantation and achieved remission. Four of the 6
67%) are dead of their underlying disease.
Subsequently, 19 additional patients were treated
ith the lower dose of Campath-1H in addition to
udarabine/TBI. Nine of these patients were in re-
ission posttransplantion; 6 had entered the trans-
lantation in remission, and 3 converted from active
isease to remission. One of the patients in remission
ubsequently progressed with their underlying disease,
died of TRM, and 3 died of GVHD. The TRM rate
as 21% (4/19), and the relapse-related mortality rate
2% (8/19). Six of the 19 patients remain alive; of
hese 6, 2 have had good response to salvage chemo-
herapy for relapsed disease.
ISCUSSION
GVHD remains a signiﬁcant problem in NMT.
ampath-1H has been shown to be an effective im-
able 4. Results Before and After Amendment
Campath-1H
100 mg
Campath-1H
50 mg
o. of patients 6 19
elapse/progression of
disease
6 (2 salvaged
with second
transplantation)
11
elated (%)/unrelated (%) 3 (50%)/3 (50%) 12 (63%)/7 (37%)
RM 0 4/19 (21%)
oss of chimerism 5 (83%) 5 (26%)
LI 3 8
VHD (grades 2-4) 2 9
210.000.00
Time (month
1.0
0.8
0.6
0.4
0.2
0.0
Probability of 
non-relapse mortalityFigure 2. Cumulative incidenceunosuppressive agent. It has been used successfully
o prevent GVHD in traditional transplantations us-
ng both related and unrelated donors [10]; therefore,
e had hoped that adding Campath-1H to ﬂudara-
ine/TBI would provide sufﬁcient immunosuppres-
ion such that cyclosporine alone could be used post-
ransplantion without the need for mycophenolate
ofetil.
Our study demonstrates that high-dose Campath-
H with ﬂudarabine/TBI results in poor engraftment
nd failure of the transplantation. Although patients en-
rafted easily with this regimen, the signiﬁcant in vivo
-cell depletion that occurred from Campath-1H and
ts long-lasting effect posttransplantation led to loss of
himerism, resulting in the need to amend the proto-
ol. Even after the amendment, 5 of 19 patients had
rogressive loss of chimerism associated with relapse.
t is difﬁcult to discern whether the relapse occurred
rst or whether loss of chimerism allowed relapse to
ccur; nonetheless, the result is ultimately the same.
nfortunately, the use of DLI in these circumstances
as of little beneﬁt in reversing the problem and only
ucceeded in helping 1 patient achieve better chimer-
sm with good disease control.
The dose of DLI chosen was a synthesis of doses
sed in other centers for the treatment of relapse. The
nterval between DLI depended on the rate of pro-
ression of the patient’s underlying relapsed disease.
After the lower dose of Campath-1H was insti-
uted, there was no clear evidence of improvement in
VHD in comparison with other published trials.
fter the amendment, we reinitiated the stopping
30.00
Censored0.00
s)
of nonrelapse mortality.
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T. Shore et al.874ules, starting with patient 7. The trial was done in
eal time, and we did not delay starting patients until
ndpoints had been reached. Therefore, although we
ould have stopped after 15 patients (patient 21), we
ctually accrued several patients at the same time, and
he endpoints were reached at around the same time,
eading to termination at patient 25. Thus, the trial
as closed after 25 patients had accrued to the study.
As expected, there was a 48% reactivation of CMV,
toxicity noted in other trials that used Campath-1H in
heir conditioning regimens. Again, this was easily man-
geable and did not pose a signiﬁcant problem for the
rial. It is not apparent why our results were not as
romising as those from other trials using Campath-1H.
More recently, Campath-1H has shown efﬁcacy in
reventing GVHD in the nonmyeloablative setting.
n 1 trial using this agent, engraftment occurred in 42
f 43 patients. At a median follow-up of 9 months, 33
atients remained in complete remission. There were
o cases of grade 3-4 GVHD and a nonrelapse mor-
ality rate of only 11% at 1 year [11]. A second report
f a nonmyeloablative conditioning regimen using
able 5. Current Status
Diagnosis/stage Response (day
1 Follicular small cleaved lymphoma/ Pod
2 MDS Pod
3 Secondary AML/CR1 Relapse
4 Secondary AML/CR1 Relapse
5 AML/PR Pod
6 Secondary AML/CR1 Relapse
7 CML/CR post blast crisis Remission
8 Secondary AML/CR1 Remission
9 Secondary AML/CR1 Remission
0 Secondary AML/CR1 Relapse
1 Hodgkin’s/rel 1 Pod
2 Hodgkin’s/rel 1 Relapse
3 AML/rel 1 Relapse
4 AML/MPD/MM Remission-AML
5 CML/CP Remission
6 Secondary AML/CR1 Relapse
7 HD/refractory relapse Remission
8 Mantle cell/rel 1 Remission
9 AML/CR2 Relapse
0 AML/CR2 Remission
1 Mantle cell/rel 1 Pod
2 Mantle cell/CR 1 Remission
3 Follicular mixed NHL Stable disease
4 AML/CR 1 Relapse
5 Large cell lymphoma/rel 2 Stable disease
CP, Pneumocystis pneumonia; pod, progression of disease; CHF,ampath-1H in the setting of unrelated stem cell nonation showed that of 47 patients, only 3 developed
rade 3-4 GVHD, and none developed extensive
hronic GVHD [12]. Furthermore, it has been shown
hat reconstitution of donor dendritic cells posttrans-
lantation is not impaired by Campath-1H given be-
ore transplantation. Thus, this novel agent is ex-
remely attractive in terms of its ability to prevent
VHD without affecting engraftment [13-18].
The beneﬁts of Campath-1H in terms of tolera-
ion of transplantation and disease control remain
ncertain. Although Campath-1H did allow for min-
mal GVHD in the related setting, this beneﬁt was
egated by the increased GVHD with DLI in that
roup. No other group appeared to gain additional
eneﬁt from adding Campath-1H to the regimen.
Thus, this trial was designed as a strategy to de-
rease or avoid GVHD while still achieving the same
eneﬁt as from other similar approaches to reduced-
ntensity allogeneic transplantation. Although the pa-
ients tolerated the transplants well, and the results
ere indeed similar to those of other trials with high-
isk malignancies, the goal of reducing GVHD was
urvival
ransplantation) Status (or cause of death)
1109 Progressive disease
1102 CR after salvage second transplant
651 Relapse, progression (8/23/04 — day 651)***
976 Relapse
145 Progression of disease (5/5/03 — day 145)***
97 Relapse/sepsis/gvhd (3/24/03 — day 97)***
842 Continued complete remission/gvhd
119 gvhd (8/14/03 — day 119)***
779 Continued complete remission
545 Relapse, sepsis, resistant bacteremia
(12/13/04 — day 545)***
60 Progression of disease (9/13/03 — day 60)***
687 Very good partial response after salvage
therapy
174 Relapse, progression (4/26/04 — day 174)***
47 C. difficile colitis/ shock (4/11/04 — day 47)***
505 Continued complete remission
269
Relapse/grade 4 gvhd due to DLI/sepsis
(12/3/04 — day 269)***
71
Continued complete remission/gvhd,
progression (7/22/04 — day 71)***
397 gvhd gut and liver gr. III, CMV viremia
(6/19/05 — day 397)***EBV, sepsis
236 Relapse, (2/7/05 — day 236)***progression
60 Gvhd (8/29/04 — day 60)***
141 Progressive of disease/gvhd (7/15/04 — day
141)***
325 Continued complete remission
310 Relapse
223
Ongoing leukemia, relapse (6/9/05 — day
223)***sepsis, acute renal fail., CHF
203
Relapse, (5/17/05 — day 203)***hypoxic resp.
failure—PCP
stive heart failure; CR, complete remission.S
s posttot realized. The use of unrelated donors and the use
o
s
1
a
t
a
a
A
m
R
1
1
1
1
1
1
1
1
1
Reduced-Intensity Conditioning Campath 875f DLI in the related donors resulted in GVHD rates
imilar to those reported in trials not using Campath-
H. Further trials may need to focus on differential
pproaches to conditioning based on whether the
ransplantation used a related or an unrelated donor
nd on anti–T-cell modalities that are not as potent or
s long-lived as Campath-1H.
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